Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Holderfield

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Biorxiv : the Preprint Server for Biology|December 25, 2025
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla T O'Toole, et al.
Cancer Research|May 22, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla O'Toole, et al.
Cancer Discovery|June 22, 2026
Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancerWilliam J McDaid, Helen Adderley, Paolo D d'Arienzo, et al.
Cancer Discovery|October 6, 2025
Correction: Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Cancer Discovery|April 9, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Science (New York, N.Y.)|July 24, 2025
A neomorphic protein interface catalyzes covalent inhibition of RAS<sup>G12D</sup> aspartic acid in tumorsCaroline Weller, G Leslie Burnett, Lingyan Jiang, et al.
Cancer Discovery|February 11, 2026
Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-refractory KRAS G12C-mutant NSCLC for Immune Checkpoint BlockadeXing Wei, Cristina Blaj, M Ali Al-Radhawi, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaUrszula N Wasko, Jingjing Jiang, Alvaro Curiel-Garcia, et al.
Nature|April 8, 2024
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Bianca J Lee, Jingjing Jiang, et al.
Nature|November 12, 2024
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N Wasko, Jingjing Jiang, Tanner C Dalton, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Biorxiv : the Preprint Server for Biology|December 25, 2025
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla T O'Toole, et al.
Cancer Research|May 22, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaMona Foth, Wontak Kim, Kayla O'Toole, et al.
Cancer Discovery|June 22, 2026
Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancerWilliam J McDaid, Helen Adderley, Paolo D d'Arienzo, et al.
Cancer Discovery|October 6, 2025
Correction: Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Cancer Discovery|April 9, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Science (New York, N.Y.)|July 24, 2025
A neomorphic protein interface catalyzes covalent inhibition of RAS<sup>G12D</sup> aspartic acid in tumorsCaroline Weller, G Leslie Burnett, Lingyan Jiang, et al.
Cancer Discovery|February 11, 2026
Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-refractory KRAS G12C-mutant NSCLC for Immune Checkpoint BlockadeXing Wei, Cristina Blaj, M Ali Al-Radhawi, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaUrszula N Wasko, Jingjing Jiang, Alvaro Curiel-Garcia, et al.
Nature|April 8, 2024
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Bianca J Lee, Jingjing Jiang, et al.
Nature|November 12, 2024
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N Wasko, Jingjing Jiang, Tanner C Dalton, et al.
Pageof 4